Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys, Inc. (NASDAQ: AMED) is a healthcare at home company that reports on developments across home health, hospice and high acuity care services delivered in the home. The Amedisys news flow includes regular earnings announcements, corporate updates and clinical program disclosures that reflect its role in the home health care services industry.
Investors and observers following AMED news can expect detailed quarterly and annual financial results, including net service revenue, net income, adjusted EBITDA and other non-GAAP measures that Amedisys reconciles to GAAP in its releases. These earnings communications often discuss factors such as merger-related expenses, impairment charges and other items that affect reported and adjusted results.
Amedisys also issues news about its clinical initiatives and partnerships. For example, the company has announced the rollout of advanced molecular testing for infection diagnosis in collaboration with Patient Choice Laboratories, aimed at improving the speed and accuracy of identifying pathogens in urine, respiratory and wound infections in the home setting. Through its subsidiary Contessa Health, Amedisys has highlighted participation in models such as the Centers for Medicare & Medicaid Services’ GUIDE Model for dementia care, reflecting activity in alternative payment and care delivery models.
Other Amedisys news items cover recognition for patient and caregiver satisfaction, such as SHPBest™ awards for home health and hospice care centers, and updates related to its merger with UnitedHealth Group, including regulatory and legal milestones. Readers who monitor AMED news gain insight into the company’s financial performance, regulatory environment, care quality indicators and the evolution of its home-based service offerings.
Amedisys, a leader in home health and hospice care, announced its participation in several upcoming investor conferences. CEO Chris Gerard and CFO Scott Ginn will present at the Benchmark Healthcare House Calls Conference on June 2, at the William Blair Growth Stock Conference on June 6, and at the Jefferies Healthcare Conference on June 8. Amedisys provides personalized healthcare services to over 445,000 patients annually and partners with more than 3,000 hospitals.
Amedisys, Inc. (NASDAQ: AMED) has been recognized as one of the 2022 Best Places to Work in Healthcare by Modern Healthcare for the second consecutive year. This distinction highlights companies that empower employees to provide exceptional care. Amedisys emphasizes creating a supportive environment for its staff, crucial during the challenges posed by the pandemic. The evaluation involved 25% from company practices and 75% from employee engagement scores. The complete list of winners will be published on September 29, 2022.
Summary not available.
Amedisys, a home health, hospice, and personal care provider, announced a series of upcoming investor presentations. CEO Chris Gerard and CFO Scott Ginn will present at the Bank of America Securities Healthcare Conference on May 10 at 5:40 p.m. ET, the RBC Capital Markets Global Healthcare Conference on May 17, and the UBS Global Healthcare Conference on May 23 at 9:15 a.m. ET. Investors can access a live webcast of these presentations through the company’s website.
Amedisys operates nationwide, serving over 445,000 patients annually with high-quality home-based care.
Amedisys, Inc. (NASDAQ: AMED) reported Q1 2022 financial results, showing a net service revenue increase of $8.2 million to $545.3 million but a decline in net income to $31.7 million from $49.9 million in 2021. Adjusted EBITDA was $66.3 million versus $78.6 million in the prior year. The company's guidance for 2022 includes anticipated adjusted revenue between $2.330 billion to $2.365 billion and adjusted diluted earnings per share of $5.23 to $5.45. CEO Chris Gerard highlighted challenges due to COVID-19 but expressed confidence in growth opportunities.
Amedisys, Inc. (NASDAQ: AMED) has promoted Nick Muscato to Chief Strategy Officer, effective immediately. Muscato has significant experience in the company, previously serving as Senior Vice President of Finance, and has been instrumental in developing the company's strategic direction. His efforts in Investor Relations have strengthened relationships with analysts and shareholders. Muscato expressed enthusiasm for continuing to enhance Amedisys’ mission of providing home-based healthcare services and improving patient care.
Amedisys, Inc. (NASDAQ: AMED) will announce its first-quarter results for the period ending March 31, 2022, after market hours on April 27, 2022. The company plans to host an investor conference call the following day at 11:00 a.m. ET to discuss these results. Interested participants can join the call via toll-free numbers or through the company's website. Amedisys specializes in home health, hospice, personal care, and high-acuity care, serving over 445,000 patients annually with more than 11.5 million visits in 38 states.
Amedisys has successfully acquired Evolution Health, enhancing its home health services footprint across Texas, Oklahoma, and Ohio. This acquisition allows Amedisys to operate under established local brands like Guardian Healthcare, expanding care options to more communities. The company now boasts 350 care centers across 34 states, servicing roughly 74,000 patients daily. Amedisys ranks as the second-largest home health provider and third-largest hospice provider in the U.S., with a commendable Quality of Patient Care (QPC) Star score of 4.33.
Amedisys, Inc. (NASDAQ: AMED) has acquired home health assets from AssistedCare Home Health and RH Homecare Services, enhancing its service offerings in North Carolina. This acquisition allows Amedisys to extend both home health and hospice services into new communities, particularly Wilmington and Greenville. With this addition, Amedisys operates 350 care centers across 34 states, serving around 74,000 patients daily. The company emphasizes its commitment to quality, holding a QPC Star score of 4.33 and recognition as a top workplace in healthcare.
Amedisys, a prominent provider of home health and hospice services, will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022, at 10:40 a.m. EST, followed by the Barclays Global Healthcare Conference on March 17, 2022, at 8:00 a.m. EST. Key executives Chris Gerard and Scott Ginn will lead the presentations. Investors can access the live webcasts on Amedisys’ official website. With over 21,000 employees and 530 care centers across 38 states, Amedisys serves more than 445,000 patients annually, conducting over 11.5 million visits each year.